The Meeting of the Transparency Council No. 27/2022 of 11.07.2022

The agenda includes:

Preparing a position on the legitimacy of granting reimbursement approval for the medicinal product Livmarli (maralixibat) for the indication: pruritus of the skin in Alagille syndrome.

Preparing an opinion on draft health policy programmes of local government units:

• “Prevention of overweight and obesity in children in class III of primary schools in the Municipality of Kolobrzeg for 2022/2024”,
• “Comprehensive rehabilitation and therapy for children with disabilities from the Municipality of Mszana”,
• “Programme for prevention and correction of posture defects in school-age children »Healthy Spine«” (Miedźna Municipality).

Preparing an opinion on the inclusion in the reimbursement of medicines containing the active substances:

• cetirizinum for the following indications: atopic dermatitis; food allergy – in patients from 6 months of age; anaphylactic reaction manifested by urticaria or Quincke’s edema – in patients from 6 months of age,
• levocetirizini dihydrochloridum for the following indications: atopic dermatitis; food allergy – in patients from 6 months of age; anaphylactic reaction manifested by urticaria or Quincke’s edema – in patients from 6 months of age,
• loratadinum for the following indications: atopic dermatitis – in patients from 2 years of age; food allergy – in patients from 2 years of age; anaphylactic reaction manifested by urticaria or Quincke’s edema –– in patients from 2 years of age,
• acidum folicum for the indication: psoriasis – in patients treated with methotrexate,
• leflunomidum for the indication: juvenile idiopathic arthritis – polyarticular form after failure of therapy or in case of methotrexate intolerance.